MBX Biosciences

Pioneering Precision Endocrine Peptides (PEPs)™ to transform the treatment of obesity and rare endocrine disorders.

[MBX Biosciences @MBXBio]

MBX Biosciences has welcomed Jeff Held as Chief Legal Officer. Jeff brings 30+ years of legal, compliance and executive leadership experience supporting innovative biotechnology and healthcare companies through key growth milestones. Read the announcement: https://t.co/Z2wROjbavm

[MBX Biosciences @MBXBio]

We are proud to announce that the first patient has been dosed in the pivotal Phase 3 oPTimize trial evaluating an investigational, once-weekly PTH replacement therapy for adults with chronic #hypoparathyroidism. Learn more: https://t.co/wCwOlH2lQ4 #RareDisease #ClinicalTrials

[MBX Biosciences @MBXBio]

From obesity to hypoparathyroidism, over 194M Americans live with chronic illness. MBX supports @IAmBiotech’s #FightOfOurLives campaign, highlighting the need for continued innovation to address unmet needs. Learn more: https://t.co/4IDrmrIoqh

[MBX Biosciences @MBXBio]

MBX Biosciences today reported financial results for the second quarter ended June 30, 2026, highlighting recent pipeline and corporate progress. View the press release: https://t.co/qjTYDl8ydj

[MBX Biosciences @MBXBio]

Looking to make an impact in biotech? At MBX Biosciences, we're advancing precision peptide therapies for obesity and hypoparathyroidism – and seeking passionate professionals to join our team. Explore our open roles: https://t.co/hZMM5k2Wu1. #Hiring #BiotechCareers #LifeSciences

[MBX Biosciences @MBXBio]

By 2035, 25% of the global population is projected to have obesity. Yet, many patients discontinue current treatments within 1–2 years, underscoring the need for more options. These insights and more from MBX’s Obesity Day: https://t.co/6AbX9CY23k

[MBX Biosciences @MBXBio]

We’re #Hiring! MBX is seeking talented professionals in Business Development, Finance, IT, Program Management and Regulatory to join us on our mission to advance treatments for endocrine and metabolic disorders. Explore our open roles: https://t.co/hZMM5k2Wu1.

[MBX Biosciences @MBXBio]

50 years of biotech progress and just getting started. MBX is proud to support @IAmBiotech’s #FightOfOurLives campaign as we advance our PEP™ platform for rare endocrine and metabolic diseases. Explore the industry’s impact over the past 50 years: https://t.co/CkCNr4EEg5

[MBX Biosciences @MBXBio]

MBX Biosciences announced full 12-week Avail™ Phase 2 results and new one-year OLE data supporting its once-weekly parathyroid hormone replacement therapy candidate in adults with chronic hypoparathyroidism. Join the webcast: https://t.co/6AbX9CY23k.

[MBX Biosciences @MBXBio]

June 1 marks #WorldHypoparaDay, spotlighting #hypoparathyroidism (HP) and the 100K+ people in the U.S. living with this rare disorder. At MBX, we’re proud to partner with @HypoPARAassoc and leverage our Precision Endocrine Peptide™ platform to continue advancing progress for HP.

[MBX Biosciences @MBXBio]

MBX to host investor webcast June 12 (8am ET) ahead of #ENDO2026 in Chicago, highlighting Phase 2 data in hypoparathyroidism.
• 1-year OLE data (June 12)
• Full 12-week results (June 13)
Join: https://t.co/6AbX9CY23k

[MBX Biosciences @MBXBio]

MBX is attending the @Jefferies 2026 Global Healthcare Conference in NYC on June 3. CEO Kent Hawryluk & CMO Sam Azoulay, M.D. will discuss progress advancing precision peptide therapies for endocrine and metabolic disorders. https://t.co/6AbX9CY23k

[MBX Biosciences @MBXBio]

On #ClinicalTrialsDay, we thank the researchers and patients who move clinical research forward. Their dedication and trust enable progress and help bring new therapies closer to those who need them most. Learn more about MBX’s clinical programs: https://t.co/Og8zA2oij6

[MBX Biosciences @MBXBio]

MBX to present Obesity Portfolio updates at Obesity Day (10:30am ET) including initial Ph1 data for MBX 4291 (GLP‑1/GIP co‑agonist). Register here: ‌https://t.co/6AbX9CY23k

[MBX Biosciences @MBXBio]

MBX announces Q1 2026 earnings and the appointment of global biopharma commercial leader, Mark Soued, MBA as Chief Commercial Officer, as the Company advances its proprietary Precision Endocrine Peptides (PEPs)™ pipeline. https://t.co/KYkTnbFlhm

[MBX Biosciences @MBXBio]

This #WorldHormoneDay, MBX joins @ESEndocrinology to spotlight the impact of hormone imbalances – from obesity to 400+ rare endocrine diseases including hypoparathyroidism. We’re advancing Precision Endocrine Peptides™ to address unmet needs. Learn more: https://t.co/TfwPd9bkvO

[MBX Biosciences @MBXBio]

MBX will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio. Register here: https://t.co/T0lb3ngt7J

[MBX Biosciences @MBXBio]

We’re #Hiring! At MBX, we’re looking for researchers and clinical & regulatory professionals to join our mission to improve care for rare endocrine and metabolic disorders. Explore our open roles: https://t.co/hZMM5k2Wu1

[MBX Biosciences @MBXBio]

This #WorldHealthDay, MBX supports the @WHO's call to #StandWithScience. With a focus on science-led innovation through our proprietary PEP™ Platform, we aim to transform the treatment landscape for endocrine and metabolic diseases. Learn more: https://t.co/TfwPd9bkvO

[MBX Biosciences @MBXBio]

This Women’s History Month, we want to thank all the talented and driven women that embody our mission, values and operating principles in support of our goal to improve the lives of people living with endocrine and metabolic disorders.